arrow_back Civic Audit
Share share

PASTEUR Act of 2026: Developing New Antibiotics and Fighting Drug Resistance

This law creates a program to develop innovative antibiotics to treat the most dangerous infections. It ensures that life-saving medicines are available when needed and that hospitals use them correctly to prevent future resistance.
Key points
The government will pay drug developers to ensure a steady supply of new, effective antibiotics for patients.
Grants will be provided to hospitals and clinics to improve how they prescribe and use these powerful medicines.
New systems will track and publicly report where and how drug-resistant 'superbugs' are spreading.
Drug companies must guarantee they can produce enough medicine to meet patient needs without shortages.
article Official text account_balance Process page notifications_active Track this Bill
Status: Introduced
Civic Will
Checking votes...
I support
I oppose
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Print number: 119_HR_7352
Sponsor: Rep. Carter, Earl L. "Buddy" [R-GA-1]
Process start date: 2026-02-04
System Note: Lustra is free, publicly auditable civic infrastructure — full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source—always verify them if you can.
Summarized by: gemini-flash-latest
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

PASTEUR Act of 2026

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_HR_7352.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2026-02-04.

What are the main provisions?

Key points include:

  • The government will pay drug developers to ensure a steady supply of new, effective antibiotics for patients.
  • Grants will be provided to hospitals and clinics to improve how they prescribe and use these powerful medicines.
  • New systems will track and publicly report where and how drug-resistant 'superbugs' are spreading.
  • Drug companies must guarantee they can produce enough medicine to meet patient needs without shortages.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Carter, Earl L. "Buddy" [R-GA-1].

What is the latest detailed status?

The latest detailed status is: Introduced in House

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2026-03-06.

What is the impact of this bill?

We don't know—that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge.

CATEGORIES

Health Economy Security